Bridge Biotherapeutics Stock Working Capital
| 288330 Stock | KRW 3,955 95.00 2.35% |
Bridge Biotherapeutics fundamentals help investors to digest information that contributes to Bridge Biotherapeutics' financial success or failures. It also enables traders to predict the movement of Bridge Stock. The fundamental analysis module provides a way to measure Bridge Biotherapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bridge Biotherapeutics stock.
Bridge |
Bridge Biotherapeutics Company Working Capital Analysis
Bridge Biotherapeutics' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
In accordance with the company's disclosures, Bridge Biotherapeutics has a Working Capital of 0.0. This is 100.0% lower than that of the Healthcare sector and about the same as Biotechnology & Medical Research (which currently averages 0.0) industry. The working capital for all Republic of Korea stocks is 100.0% higher than that of the company.
Did you try this?
Run Odds Of Bankruptcy Now
Odds Of BankruptcyGet analysis of equity chance of financial distress in the next 2 years |
| All Next | Launch Module |
Bridge Fundamentals
| Return On Equity | -75.4 | |||
| Current Valuation | 29.26 B | |||
| Shares Owned By Insiders | 30.27 % | |||
| Shares Owned By Institutions | 9.09 % | |||
| Revenue | 1.92 B | |||
| Gross Profit | (1.12 B) | |||
| EBITDA | (21.27 B) | |||
| Net Income | (26.28 B) | |||
| Cash And Equivalents | 8.2 B | |||
| Total Debt | 53.63 M | |||
| Current Ratio | 1.05 X | |||
| Cash Flow From Operations | (21.13 B) | |||
| Market Capitalization | 217.07 B | |||
| Total Asset | 46.66 B | |||
| Net Asset | 46.66 B |
About Bridge Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bridge Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bridge Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bridge Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Bridge Biotherapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bridge Biotherapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bridge Biotherapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Bridge Stock
Moving against Bridge Stock
| 0.59 | 041510 | SM Entertainment | PairCorr |
| 0.58 | 035420 | Naver | PairCorr |
| 0.57 | 032640 | LG Uplus | PairCorr |
| 0.36 | 078160 | MEDIPOST | PairCorr |
| 0.35 | 011390 | Busan Industrial | PairCorr |
The ability to find closely correlated positions to Bridge Biotherapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bridge Biotherapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bridge Biotherapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bridge Biotherapeutics to buy it.
The correlation of Bridge Biotherapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bridge Biotherapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bridge Biotherapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bridge Biotherapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Bridge Stock
Bridge Biotherapeutics financial ratios help investors to determine whether Bridge Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Bridge with respect to the benefits of owning Bridge Biotherapeutics security.